Like this, in the SETUP (Sequential Evaluation of Tumors Undergoing Preoperative Chemotherapy) trial, TNBC patients with low tumor IRF9 expression during chemotherapy had a seven-fold higher rate of metastatic recurrence. The gene discussed is IRF9; the disease is neoplasm.